Endometrioid Carcinoma of the Ovary
Fig. 15.1 EOC grade 1 Fig. 15.2 EOC grade 3 Adequate sampling of the tumors should enable to establish whether EOC arises in endometriosis, adenofibromatous endometrioid precursors, or de novo….
Small Cell Carcinoma of the Ovary
© Springer International Publishing Switzerland 2017Eric Pujade-Lauraine, Isabelle Ray-Coquard and Fabrice Lécuru (eds.)Ovarian Cancers10.1007/978-3-319-32110-3_20 20. Small Cell Carcinoma of the Ovary Patricia Pautier1 , Aurélie Auguste2 and Alexandra Leary1, 2 (1) Département de médecine oncologique, Gustave Roussy, Université Paris-Saclay, F-94805,…
Mucinous Carcinoma of the Ovary
Fig. 16.1 (Courtesy of Drs/Treilleux, D Pissaloux and Pr/Ray-Coquard from centre leon berard, Lyon) While the low incidence is a barrier to performing effective clinical trials specific to MOC, international…
Clinical Research in France, Europe, and in the World Dedicated to Ovarian Cancers
Gynecological cancer trial groups represented in European Network of Gynecological Oncological Trial Groups Study group (country) AGO – Austria, Arbeitsgemeinschaft Gynäkologische Onkologie Austria AGO Study Group, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe,…
Clear Cell Carcinoma
© Springer International Publishing Switzerland 2017Eric Pujade-Lauraine, Isabelle Ray-Coquard and Fabrice Lécuru (eds.)Ovarian Cancers10.1007/978-3-319-32110-3_14 14. Clear Cell Carcinoma Masashi Takano1 , Satoshi Takakura2 and Keiichi Fujiwara3 (1) Department of Clinical Oncology, National Defense Medical College Hospital, 3-2 Namiki, Tokorozawa Saitama, 359-8513,…
The Future in Ovarian Cancer: Advances in Immunotherapies
Fig. 11.1 The major T cell-based immunotherapeutic targets and their tumor or antigen-presenting cell ligands. The activation of T cells and their conversion to a cytotoxic phenotype is governed by…
High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors
PARP inhibitor Company PARP inhibition Details Olaparib (AZD2281) AstraZeneca PARP 1/2/3 Licensed in EU for maintenance BRCAm; ≥3rd line (FDA) in BRCAm. Phase III trials with tablet formulation – first…
Genetics of Ovarian Carcinomas
Fig. 2.1 BRCA, DNA repair and the cell cycle (Foulkes and Shuen [9]). In response to DNA damage, BRCA1 mediates HR (depicted in the outer ring) and cell cycle regulation…
Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or Peritoneum
Gene mutation Serous tumor of LMP Low-grade serous carcinoma References TP53 0–8 % 0–8.3 % [30, 82] KRAS 33–61.8 % 19–41 % [11, 31, 82, 108] BRAF 14.5–28 % 2–33…
Treatment at Relapse (Surgery and Systemic Treatments)
Fig. 10.1 Criteria for decision making When Should the Relapse Be Treated? In most of cases, CA 125 elevation is the first signal of recurrence; it can be observed some…
